14 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
| FY | Revenue | Net income | Gross M | Op M | ROE | ROA | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|---|---|
| 2025 | $42M | $168M | 67.2% | -429.5% | 275.4% | 65.0% | — | — | $89M |
| 2024 | $26M | $29M | 66.9% | -756.6% | -21.6% | 6.4% | — | — | $126M |
| 2023 | $1M | -$238M | 64.0% | -17716.6% | 123.0% | -37.8% | -$175M | — | $103M |
| 2022 | $211M | -$292M | 66.8% | -121.7% | 212.3% | -60.7% | -$243M | — | $64M |
| 2021 | $327M | -$287M | 82.4% | -80.8% | -293.8% | -42.3% | -$39M | — | $417M |
| 2020 | $476M | $132M | 92.1% | 32.9% | 47.1% | 15.7% | $147M | — | $541M |
| 2019 | $356M | $90M | 95.2% | 30.3% | 85.4% | 22.0% | $27M | $74M | $178M |
| 2018 | $0 | -$209M | — | — | 542.5% | -210.5% | -$160M | $0 | $72M |
| 2017 | $2M | -$238M | 0.0% | -14918.8% | -780.0% | -146.5% | -$205M | — | $127M |
| 2016 | $189M | -$127M | 0.0% | -61.2% | -620.3% | -71.3% | -$259M | — | $125M |
| 2015 | — | -$223M | — | — | 3596.9% | -105.1% | — | — | $158M |
| 2014 | — | -$87M | — | — | -130.4% | -46.5% | — | — | $150M |
| 2013 | — | -$54M | — | — | 55.2% | -113.0% | — | — | $40M |
| 2012 | — | -$33M | — | — | — | — | — | — | $15M |
| Quarter | Revenue | Net income | Gross M | Op M | ROE | ROA | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|---|---|
| Jun '26 | $14M | -$21M | 70.4% | -226.0% | -33.9% | -10.8% | — | — | $83M |
| Mar '26 | $12M | -$38M | 69.0% | -293.7% | -48.7% | -14.4% | — | — | $115M |
| Dec '25 | $13M | -$38M | 68.3% | -359.9% | -61.7% | -14.6% | — | — | $89M |
| Sep '25 | $12M | -$36M | 67.8% | -383.1% | -40.5% | -6.9% | — | — | $103M |
| Jun '25 | $10M | $298M | 66.9% | -443.6% | 248.5% | 67.8% | — | — | $217M |
| Mar '25 | $8M | -$57M | 65.1% | -597.9% | 30.8% | -15.2% | — | — | $82M |
| Dec '24 | $8M | -$51M | 64.4% | -586.9% | 38.4% | -11.3% | — | — | $126M |
| Sep '24 | $6M | -$11M | 54.9% | -774.2% | 12.2% | -2.1% | — | — | $98M |
| Jun '24 | $10M | -$13M | 82.4% | -384.9% | 15.4% | -1.9% | — | — | $159M |
| Mar '24 | $2M | $103M | 37.7% | -2937.0% | -125.7% | 13.5% | — | — | $260M |
| Dec '23 | $92M | -$80M | 7.6% | -75.3% | 41.2% | -12.7% | -$13M | — | $103M |
| Sep '23 | $75M | -$40M | 56.1% | -42.9% | 29.7% | -6.8% | -$54M | — | $80M |
| Jun '23 | $59M | -$43M | 57.7% | -58.8% | 24.5% | -9.1% | -$39M | — | $73M |
| Mar '23 | $32M | -$76M | 48.0% | -208.9% | 38.5% | -18.8% | -$69M | — | $16M |
| Dec '22 | $45M | -$59M | 68.7% | -113.5% | 42.8% | -12.2% | -$100M | — | $64M |
| Sep '22 | $45M | -$87M | 22.4% | -177.1% | 89.2% | -15.7% | -$38M | — | $287M |
| Jun '22 | $60M | -$50M | 81.3% | -73.2% | 221.6% | -9.2% | -$51M | — | $275M |
| Mar '22 | $60M | -$96M | 84.4% | -134.6% | -764.8% | -16.2% | -$55M | — | $326M |
| Dec '21 | $73M | -$46M | 83.5% | -53.9% | -46.8% | -6.7% | -$53M | — | $417M |
| Sep '21 | $83M | -$39M | 74.2% | -39.7% | -29.5% | -5.2% | $13M | — | $361M |
How the market has priced CHRS against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
Over the past 5 years, Coherus Oncology, Inc.'s revenue has declined 38.4% per year, and net income grown 4.9% per year. These are computed facts, not advice.
As of FY2025, Coherus Oncology, Inc. reported — of total debt against $89M of cash; operating income covered interest expense -20.1×.
In FY2025, gross margin was 67.2%, operating margin -429.5%, and net margin 398.4%.
As of Sep '26, Coherus Oncology, Inc. traded at a price-to-earnings ratio of about 1.3× (market cap ÷ latest annual net income). The valuation charts above show how its P/E, P/S have moved with the share price. These are computed facts, not advice.
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.